Moleculin Biotech, Inc. (MBRX) Return on equity 2016–2025
Moleculin Biotech, Inc. (MBRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-223.6%FY2025 · since FY2016: -26.2% → -223.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -223.6% | +8.8 pp |
| FY2024 | -232.4% | -136.2 pp |
| FY2023 | -96.3% | -40.6 pp |
| FY2022 | -55.6% | -35.5 pp |
| FY2021 | -20.1% | +77.6 pp |
| FY2020 | -97.7% | -12.9 pp |
| FY2019 | -84.8% | -1.6 pp |
| FY2018 | -83.2% | -25.9 pp |
| FY2017 | -57.3% | -31.0 pp |
| FY2016 | -26.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice